

Patient's perspective: emotional impact of the COVID-19 pandemic in psoriasis patients treated with biological drugs and small molecules in real clinical practice

First published: 08/06/2020

Last updated: 21/07/2020

Study

Finalised

Administrative details

EU PAS number

EUPAS35712

Study ID

36445

DARWIN EU® study

No

Study countries

☐ Spain

Study description

The current COVID-19 pandemic may have had an impact not only on patients' health, but also on their social behaviour and their perception of vulnerability resulting from exposure to immunosuppressive/immunomodulatory psoriatic drugs. We sought to clarify the status of these patients with respect to possible COVID-19 involvement and to detect changes in their treatment regimen, the reason why they made them as well as the influence in their social behaviour. We conducted a retrospective study and included 174 patient under biologics or small molecules during the onset and the development of the crisis. We found a not significant incidence of COVID-19 infection and we bring to light emotional impact of pandemic in this group of patients, as an increased worry about their immunosuppressed status has been evidenced. Individuals also took additional measures to protect themselves and looked for information on internet. COVID-19 pandemic has not only had an impact on health, but also on the emotional sphere of psoriatic patients.

Study status

Finalised

Research institutions and networks

Institutions

[Hospital Universitario Príncipe de Asturias](#)

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Ana Rodríguez-Villa Lario anarvlario@gmail.com

Study contact

anarvlario@gmail.com

Primary lead investigator

Ana Rodríguez-Villa Lario

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 02/03/2020

Actual: 02/03/2020

Study start date

Planned: 09/03/2020

Actual: 09/03/2020

Date of final study report

Planned: 08/06/2020

Actual: 08/06/2020

Sources of funding

- Pharmaceutical company and other private sector

- Non-for-profit organisation (e.g. charity)
- EU institutional research programme
- Other

More details on funding

Name of Pharmaceutical companies, Charities, Government body, Research councils, EU funding scheme, Other: not provided

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Drug utilisation

Data collection methods:

Combined primary data collection and secondary use of data

Main study objective:

We sought to clarify the status of patients on immunosuppressive or immunomodulator drugs with respect to possible COVID-19 involvement and to detect changes in their treatment regimen, the reason why they made them as well as the influence in their social behaviour.

Study Design

Non-interventional study design

Cross-sectional

Other

Non-interventional study design, other

Retrospective study

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(L04AC13) ixekizumab

ixekizumab

(L04AC13) ixekizumab

ixekizumab

(L04AC10) secukinumab

secukinumab

(L04AA32) apremilast

apremilast

(L04AB04) adalimumab

adalimumab

(L04AC16) guselkumab

guselkumab

Medical condition to be studied

Psoriasis

Population studied

Short description of the study population

Psoriasis patients under treatment in our Hospital during the last year. Inclusion criteria were psoriasis being under biologics or small molecules during the onset and the development of the crisis, verbal consent and adulthood. Exclusion criteria included impossibility of telephone contact or refusal to participate.

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)

- Adults (85 years and over)

Special population of interest

Immunocompromised

Estimated number of subjects

174

Study design details

Data analysis plan

A statistical analysis was performed with chi-squared, Fisher exact tests and Student's t-test using Statistical Package for Social Sciences (SPSS®) for Windows, version 25.0 (Armonk, NY: IBM Corp).

Documents

Study results

[Patient's perspective psychological burden of the COVID 19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in.pdf \(1.17 MB\)](#)

Study publications

[Rodríguez-Villa Lario A, Vega-Díez D, González-Cañete M, et al. Patient's persp...](#)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Drug dispensing/prescription data](#)

[Patient surveys](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No